1223 results about "Blood cell" patented technology

The disclosure relates to immune cells for treatment of blood cancer comprising an activator receptor comprising an extracellular ligand binding domain specific to an activator antigen expressed by blood cancer cells and an inhibitor receptor comprising an extracellular ligand binding domain specific to an inhibitor antigen expressed by non-cancerous blood cells.

The invention relates to the technical field of target detection, and discloses a blood cell detection method based on improved YOLOv8. According to the method, a convolutional attention module (CBAM) is introduced, so that the detection performance of the model on a shielded small target is improved; a new loss function S-MPDIOU is set, so that the accuracy and robustness of the loss function are further improved; the multi-scale feature fusion technology is adopted to better capture blood cell information of different sizes, so that the model can more accurately identify small target platelets; the recall rate is improved by improving a non-maximum suppression (NMS) algorithm, and particularly under the condition of dense blood cells or complex forms, the improved NMS algorithm can more effectively solve the overlapping problem and reduce false detection and missing detection. Through testing, the model can accurately identify and position different types of blood cells such as red blood cells, white blood cells and blood platelets in an image, and a new effective method is provided for blood cell detection.

The present application provides a test kit and a POCT blood cell analyzer. The test kit includes a box body, a sealing ring, a microporous sheet, and a back pool body. The box body includes a front pool and a mounting cavity connected to the front pool; the sealing ring is arranged in the mounting cavity and is located on the side of the mounting cavity close to the front pool; the microporous sheet is provided with micropores that allow cells to pass through one by one; the microporous sheet is arranged in the mounting cavity and is located on the side of the sealing ring away from the front pool; the back pool body abuts against the side of the microporous sheet away from the sealing ring, and is used to fix the microporous sheet and the sealing ring on the box body; the back pool body is formed with a drainage cavity, and the front pool and the drainage cavity are connected through micropores. The test kit provided by the present application has a simple structure, is easy to assemble, and is conducive to the processing of the test kit.

Methods and devices for analyzing a sample from a subject are provided. A device includes one or more coherent light sources and one or more partially coherent light sources. The light sources are configured to emit first and second wavelengths of electromagnetic radiation towards an imaging chamber configured to hold blood cells. The light sources are aligned to illuminate a single common area of the imaging chamber. The device includes optics positioned to receive light from the imaging chamber, and a detector in optical communication with the optics. The detector is configured to detect fluorescence emission and backscatter from blood cells when present in the imaging chamber. The device includes mixers / unmixers configured to replicate and mix first and second signals representative of the responses to the first and second wavelengths after interacting with the plurality of blood cells to generate spectro-spatial responses.

The invention provides a blood cell image recognition method based on a multi-scale Vision Transform model, and the method comprises the steps: constructing a multi-scale feature extraction architecture, combining the global modeling capability of a Transform network, carrying out the parallel processing of Patches of different sizes, and fusing the multi-scale information, thereby achieving the recognition of a blood cell image. The cells in the blood smear can be comprehensively perceived from microscopic details to macroscopic contexts, so that not only is the adaptability of the model to cell size difference and morphological diversity enhanced, but also the recognition stability under the conditions of cell overlapping and dyeing difference in a complex visual field is improved; the accuracy and calculation efficiency of cell classification and counting are effectively improved, and full-process automation from visual field quality evaluation to automatic cell recognition and counting is achieved.

The invention relates to a medical image processing and recognition technology, in particular to a blood cell automatic detection method based on a grading strategy, which comprises the following steps: acquiring a blood cell image set with a label, performing data enhancement on the data set to obtain a first training data set, and selecting a minority class of samples in the first training data set as a second training data set; training a secondary classification network by using the second training data set; constructing an improved YOLOv8 target detection algorithm model, and if the category output by a detection head in the YOLOv8 target detection algorithm model is not a minority category, directly outputting a detection result; and if the category of the single cell image output by the detection head is a minority category, inputting the single cell image into a pre-trained secondary classification network, and obtaining a final category probability by combining the confidence of the secondary classification network with an improved YOLOv8 target detection algorithm model. The method can improve the detection accuracy and the detection rate, and is suitable for the scene of peripheral blood cell detection.

Disclosed are methods of treating a subject having clinically significant signs and symptoms associated with blood cell differentiation and treated with an agent that reduces the level and / or activity of BRG1 and / or BRM. The methods disclosed herein may include, e.g., administering to the subject an effective amount of a corticosteroid, hydroxyurea, or furosemide, or subjecting the subject to leukapheresis.

Disclosed are methods, means, and compositions of matter useful for the stimulation of angiogenesis directly by administration of membrane vesicles, such as fibroblast-derived exosomes, and / or through induction of angiogenic cytokines from blood cells contacted with fibroblast-derived exosomes. The invention provides means of treating conditions in which angiogenesis is beneficial through local or systemic administration of exosomes, including those derived from fibroblasts, wherein the fibroblasts are cultured under basal conditions or conditions of hypoxia. In other embodiments exosomes derived from fibroblasts are utilized to augment endogenous regenerative processes, such as hematopoiesis, angiogenesis and neurogenesis, as well as augment regenerative processes stimulated by administration of exogenous therapeutics such as cells, growth factors, or genes.

The present disclosure relates to compositions and methods of increasing levels of fetal hemoglobin (HbF) in cells. The present disclosure further relates to methods for treating patients suffering from blood cell diseases, including those associated with reduced amounts of functional adult hemoglobin (HbA), such as sickle cell disease and β-thalassemias

A blood cell-based therapeutic agent delivery system is disclosed. A blood cell-based therapeutic agent delivery vehicle is useful for delivering a therapeutic agent into a recipient organ cell. The blood cell-based therapeutic agent delivery vehicle is made by a method comprising encapsulating the therapeutic agent into a lipid nanoparticle to produce a therapeutic agent-containing lipid nanoparticle, and transfecting the therapeutic agent- containing lipid nanoparticle into a blood cell by incubating the therapeutic agent-containing lipid nanoparticle with the blood cell to form a transfected blood cell. The administration of the transfected blood cell causes the transfected blood cell to be in close proximity to or direct contact with the recipient organ cell, thereby causing a transfer of the therapeutic agent into the recipient organ cell. A composition for a blood cell-based therapeutic agent delivery vehicle for use in delivering a therapeutic agent into a recipient organ cell is also disclosed.

The invention provides a blood smear device and method for a clinical laboratory. The method comprises the following steps: collecting a staining image of a blood smear; segmenting a gathering region and a sparse region of the blood cells in the blood smear from the dyed image, and determining edge features of each blood cell in the dyed image; performing overlapping analysis on the overlapped blood cells in the aggregation area based on the edge features of the blood cells in the aggregation area to obtain an overlapping influence area of the blood cells in the aggregation area; based on the edge features of the blood cells in the sparse region, reconstructing gaps among the blood cells in the sparse region to obtain a gap reconstruction region of the blood cells in the sparse region; determining the density distribution characteristics of the blood cells in the dyeing image according to the overlapping influence area and the gap reconstruction area; and detecting the uniformity of the blood smear according to the density distribution characteristics. By adopting the scheme of the invention, the blood cell distribution condition can be accurately identified under complex interference factors.

In some embodiments, a method for classifying elements of a blood sample is provided, the method including: digitally staining an image of the blood sample using a trained machine learning model to generate a digitally stained image; extracting one or more intermediate features generated by the trained machine learning model during the digital staining of the image; providing the one or more extracted intermediate features to a trained multi-class classifier; and employing the trained multi-class classifier to classify at least one element in the blood sample based on the one or more extracted intermediate features. Many other embodiments are also provided.

A blood cell analyzer (100) and a blood cell analysis method (300). The blood cell analysis method (300) comprises: sucking a blood sample to be tested; preparing a first determination sample and obtaining first optical information; preparing a second determination sample and obtaining second optical information; generating a first leukocyte classification scatter diagram and a second leukocyte classification scatter diagram; determining a first counting result of neutrophils of the to-be-detected blood sample based on the first leukocyte classification scatter diagram and the second leukocyte classification scatter diagram; determining an actual distribution area of neutrophils from the first leukocyte classification scatter diagram; based on a reference distribution region of neutrophils of a reference leukocyte classification scatter diagram of the normal blood sample, determining a leaf-division nucleophore distribution region from the actual distribution region; determining a second counting result of the cells falling into the leaf-separating nucleogranulocyte distribution area; and based on the first counting result and the second counting result, determining a counting result of the rod-shaped nuclear granulocytes in the to-be-detected blood sample.

The present invention relates to a method for preparing a mammalian vascular network or mature mammalian bone marrow organoid. Also provided is the use of the prepared vascular network or mammalian bone marrow organoid in the treatment of bone marrow-related diseases, in vitro generation of BMO or mammalian blood cells, as a model system for the pathogenesis of bone marrow-related diseases, and as a system for identifying and / or testing pharmaceutically effective compounds for the treatment or prevention of bone marrow-related diseases.

The present disclosure describes gene editing systems and therapeutics for use in treating VEXAS syndrome. In particular, the disclosure describes lipid nanoparticles that enhance the targeted delivery of gene editing systems and therapeutics to blood cell progenitor cells, enabling treatment of VEXAS syndrome, in vivo or ex vivo.

The invention discloses a portable blood cell real-time classified counting system and method based on a big data algorithm, and relates to the technical field of biomedical engineering. Aiming at the problems of insufficient portability, poor real-time performance and difficulty in complex cell feature recognition of traditional blood cell classification counting equipment, the system realizes fusion acquisition of high-resolution cell images and dynamic spectral information through a multi-modal image acquisition module; according to the system, intelligent preprocessing and multi-scale feature extraction of cell images are completed by using a self-adaptive preprocessing unit and a lightweight feature extraction engine; according to the system, cell classification algorithm optimization based on meta-learning and clinical knowledge is realized by means of a big data enhancement classifier; according to the system, an intelligent interaction terminal and an ultra-low power consumption hardware architecture are combined, so that real-time visualization of a cell classification result and miniaturization integration of equipment are realized; and finally, in a portable scene, the accuracy, the real-time performance and the equipment usability of blood cell classification counting are remarkably improved.

The invention discloses an anti-lipopolysaccharide factor rALF-like protein and application thereof, and belongs to the technical field of molecular biology. The anti-lipopolysaccharide factor rALF-like protein provided by the invention belongs to secretory protein, the rALF-like protein can be competitively combined with an LPS structural domain of bacteria to achieve the purpose of inhibiting inflammation, and the expression of the coding gene Pv-ALF-like gene in blood cells, hepatopancreas, gill and intestinal tissues is remarkably up-regulated, so that the anti-lipopolysaccharide factor rALF-like protein can be used for inhibiting inflammation. The rALF-like protein disclosed by the invention has antibacterial and antiviral effects, lays a foundation for developing antibacterial and antiviral drugs and functional feed additives, and plays an important role in improving the resistance link of prawns.

The invention relates to the field of plasma separation and detection, in particular to a composition for separating plasma and a using method thereof. The composition comprises: a phase change component, which is selected from n-alkanes, which are selected from at least one of n-tetradecane, n-pentadecane, n-hexadecane, n-heptadecane, n-octadecane, n-nonadecane, n-eicosane, n-heneicosane or n-docosane; a liquid phase carrier component, wherein the liquid phase carrier component is selected from silicone oil; the structural framework and rheology regulation and control component comprises fumed silica, and the structural framework and rheology regulation and control component comprises fumed silica; the dispersion and stabilization auxiliary agent component is selected from at least one of TiO2 and BaSO4, the density adjusting filler component is selected from at least one of TiO2 and BaSO4, and the dispersion and stabilization auxiliary agent component comprises a silane coupling agent. According to the device, plasma and blood cells can be reliably, rapidly and effectively separated only through one-time low-temperature centrifugation, and remixing caused by transportation jolting can be avoided.

A reagent for β-glucan measurement without requiring a horseshoe crab hemocyte extract by using horseshoe crab-derived factor D in the reagent for β-glucan measurement.

The invention discloses a diluent for blood cell detection, the diluent comprises a buffer solution, an osmotic pressure regulator, a preservative and a stabilizer, the concentration of the buffer solution is 5-100 mM, the osmotic pressure regulator accounts for 0.1-2% by mass, the preservative accounts for 0.01-0.05% by mass, the stabilizer accounts for 0.0001-0.05% by mass of the diluent, and the pH value of the diluent is 7.4-7.8; according to the invention, the buffer solution, the osmotic pressure regulator and the preservative in the range are compounded, so that the formed diluent has excellent chemical and physical properties; by adding the stabilizer, the diluent can keep stable for a long time, the influence of micron-sized bubbles on detection is effectively reduced, and the detection accuracy and precision are improved.

The current application reveals a method, apparatus, device, and storage medium for detecting micro residual lesions, falling within the domain of medical detection technology. This method is based on differentiated deep whole-exome / targeted drug sequencing and tissue-blood cell-plasma co-capture technology, and 100,000× ultra-high depth personalized / high evidence hotspot combination panel sequencing to evaluate tiny residual lesions and tumor evolution / second primary in plasma samples. It resolves the challenges of existing techniques, such as elevated tissue detection thresholds, restricted tracking locations, inadequate detection sensitivity and precision, or elevated costs when ctDNA concentrations in the bloodstream are minimal. Furthermore, it surmounts the challenge of simultaneously achieving personalized tracking detection and monitoring tumor evolution or second / primary detection. It markedly boosts the precision of forecasting the likelihood of recurrence following patient therapy within a restricted budget.

Provided herein are genetically modified hematopoietic cells with reduced expression or activity of: (i) one or more CRL5 complex genes, and / or (ii) one or more genes orthogonal to the CRL5 complex, that exhibit improved therapeutic potential compared to wild-type hematopoietic cells, as well as methods of generating and using genetically modified hematopoietic cells for the treatment of a disease, such as cancer.

The utility model discloses a portable peripheral blood cell counter which comprises a glass slide and a cover glass, and the cover glass is positioned at the upper end of the glass slide; the carrying and placing frame is arranged at the lower end of the glass slide, a rectangular placing open groove is formed in the upper end face of the carrying and placing frame, L-shaped positioning pieces are fixed to the four corners of the upper end of the rectangular placing open groove in the carrying and placing frame, and the glass slide is located in the rectangular placing open groove and clamped among the four L-shaped positioning pieces; the semicircular through groove is formed in the middle of the front end face and the rear end face of the carrying and placing frame, and the semicircular through groove vertically penetrates through the carrying and placing frame. According to the blood cell counter, external protection of glass slides and cover glass is achieved, the effect that each group of cover glass and glass slides are separated is achieved, and therefore the problems that a main body of an existing blood cell counter used for counting is made of glass slides and cover glass, the glass slides and the cover glass are prone to colliding with each other during placement, damage can occur, and peripheral blood cell counting is affected are effectively solved.

The invention relates to the technical field of blood cell detection, and provides an intelligent blood cell detection device and a blood cell image splicing method.The intelligent blood cell detection device comprises a device shell, a base, a micro-motion positioning assembly, an imaging support, an observation assembly, a placement table and a two-way positioning assembly, the base is fixedly installed in the device shell through the damping foot pad, the micro-motion position adjusting assembly is installed on the base, the imaging support is installed on the micro-motion position adjusting assembly, the observation assembly is installed on the imaging support, the placing table is arranged on the base, and the bidirectional position adjusting assembly is installed on the base. According to the technical scheme, the problems that in the prior art, when a specimen is subtly observed, the observation position is difficult to accurately adjust in a small distance, adjacent images are difficult to obtain, and meanwhile the images are difficult to accurately splice are solved.

The invention relates to the technical field of blood cell analysis, and particularly discloses a blood cell analysis system and method based on computer vision, which uses an image recognition and generation technology based on computer vision to carry out grid division and semantic feature extraction on blood image data. Performing global text generation and semantic coding on each blood image data grid block feature after semantic extraction so as to perform adjustment response aggregation on attention of different blood local areas in each blood image data grid block feature according to blood image text description semantic features; therefore, intelligent optimization of the blood image data is realized. In this way, the complex deep-layer mutual influence association relationship between cells can be captured, so that a more accurate diagnosis basis is provided. Meanwhile, the processing strategy can be dynamically adjusted according to the specific description content of the blood image so as to better adapt to diversified samples, and the method does not only depend on fixed preprocessing parameters.

The present invention relates to the technical field of cell morphology detection. Disclosed are a remote-assisted intelligent blood cell recognition method and apparatus, and a storage medium. The method comprises the following steps: making a peripheral blood cell smear, and scanning a cell image; performing noise processing and isolated-point removal on the cell image on the basis of a first algorithm and a second algorithm; segmenting the cell image into a background area and a target area on the basis of a grayscale value of the cell image; obtaining color features of the cell image on the basis of a color page model, and processing the color features by means of both boundary transformation and morphological transformation, so as to obtain boundary features and morphological features of cells in the cell image; and performing recognition on the boundary features and the morphological features on the basis of a constructed recognition space, and outputting matched cell types. In the present application, an optimization process is added in a cell recognition process, and a coverage problem is taken into consideration from a local area first, and is then extended from the local to the entity, thereby ensuring the comprehensiveness of recognition, and improving the recognition precision.

The present invention relates to methods and products for assessing autophagic flux, and more specifically provides a biochemical functional measure used to quantify autophagic flux in sub-populations of blood cells. The present invention also provides lysosomal system markers for use in the methods described herein, systems for assessing autophagic flux, methods of identifying markers indicative of autophagic flux, and methods of treating subjects found to be suffering from, or susceptible to, a disease, condition or state associated with autophagic flux dysfunction using the methods described herein.

Fluid analyzation devices, methods, and systems are disclosed including an analyzation device comprising a sample vessel having an outer surface, a microchannel within the confines of the outer surface, a first port extending through the outer surface to the microchannel, and a second port extending through the outer surface to the microchannel; and an piezo transducer bonded to the outer surface of the sample vessel to form a monolithic structure, the piezo transducer configured to emit ultrasonic acoustic waves having a first frequency, a second frequency, and a third frequency into and / or to a blood sample within the microchannel, the first frequency configured to begin separation of red blood cells and plasma in the blood sample, the second frequency configured to complete separation of the red blood cells and plasma, and the third frequency configured to rupture cell walls of the blood cells producing a lysed blood sample.

Techniques are provided for accurately detecting a mutation in a cell-free nucleic acid shed from a tissue (e.g., a tumor) into blood. An example technique can distinguish between a mutation in a cell-free nucleic acid molecule derived from blood cells and a mutation in a cell-free nucleic acid molecule derived from a tumor. A cell-free sample (e.g., plasma or serum) and a cellular sample (e.g., white blood cells in a buffy coat) can be sequenced. After applying filtering criteria to respective sets of sequence reads, a particular mutation can be detected in both the cell-free sample and the cellular sample. Confidence intervals for the detection of the mutation can be determined for both samples, with an upper bound for the cellular sample and a lower bound of the cell-free sample being used to determine the origin of the mutation in the cell-free sample.

The invention provides a precise magnetic control whole blood rare cell flow magnetic separation system, a magnetic separation and identification method and application, and belongs to the technical field of micro-control flow biological detection. According to the invention, the magnetic separation chip can form a gradient magnetic field, and cells are fixed at a certain position on the sealing film under the combined action of magnetic field force and friction force, so that the separation of the cells is realized. Whole blood cell detection is carried out based on the gradient magnetic field, whole blood sample loading treatment can be directly carried out, the problem that the capture rate is reduced due to mechanical death, damage and stress gene expression caused by repeated elution / transfer steps is avoided, and the capture efficiency and cell activity of the chip are guaranteed; the magnetic field provided by electricity is not needed, the cost is low, the detection accuracy is high, the problems existing in existing CTC detection are solved, economic and practical values are achieved, further development of CTC detection can be promoted, and a novel and effective method is provided for complete blood cell separation detection.